What's Happening?
Reflow Medical has reported positive six-month results from the DEEPER CORONARY study, evaluating the Spur Elute Sirolimus-Eluting Retrievable Stent System for coronary in-stent restenosis (ISR). The study, presented at EuroPCR 2026, showed 100% freedom
from major adverse cardiac events and all-cause mortality among participants. The Spur Elute system, featuring radially expandable spikes and an integrated balloon, is designed to enhance drug uptake and support arterial healing without leaving a permanent implant.
Why It's Important?
The successful results of the Spur Elute system could represent a significant advancement in the treatment of coronary artery disease, particularly for patients with ISR. By providing a temporary scaffold that enhances drug delivery and supports arterial healing, this technology could reduce the need for repeat interventions and improve long-term patient outcomes. The innovation also highlights the potential for retrievable stent systems to transform cardiovascular treatment paradigms.
What's Next?
Reflow Medical plans to continue clinical evaluations of the Spur Elute system, potentially expanding its application to other forms of coronary artery disease. The company will likely seek regulatory approval based on further study results. If successful, this technology could be adopted widely in clinical practice, offering a new option for patients and healthcare providers in managing complex cardiovascular conditions.
